Sign Out
Adjuvant treatment of HER2-positive early carcinoma of breast
Adult: Available preparations:
Pertuzumab 600 mg and trastuzumab 600 mg per 10 mL of solution for inj
Pertuzumab 1,200 mg and trastuzumab 600 mg per 15 mL of solution for inj
In combination with chemotherapy, in patients at high risk of recurrence: Loading dose: 1,200 mg pertuzumab/600 mg trastuzumab, via inj in the thigh over approx 8 minutes. Maintenance dose: 600 mg pertuzumab/600 mg trastuzumab every 3 weeks, given via inj in the thigh over approx 5 minutes for a total of 1 year (up to 18 cycles) or until disease recurrence or unmanageable toxicity occurs (whichever comes first). Missed dose: <6 weeks (time between 2 sequential inj): Administer maintenance dose as soon as possible then continue with the every 3 weeks schedule; ≥6 weeks (time between 2 sequential inj): Readminister loading dose followed by maintenance doses of every 3 weeks thereafter. Switching from IV pertuzumab and trastuzumab: <6 weeks since last IV pertuzumab and trastuzumab dose: Administer SC maintenance dose and every 3 weeks for subsequent administrations; ≥6 weeks since last IV pertuzumab and trastuzumab dose: Administer SC loading dose followed by SC maintenance doses of every 3 weeks for subsequent administrations. Dosing interruption, or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline).
Pertuzumab 600 mg and trastuzumab 600 mg per 10 mL of solution for inj
Pertuzumab 1,200 mg and trastuzumab 600 mg per 15 mL of solution for inj
In combination with chemotherapy, in patients at high risk of recurrence: Loading dose: 1,200 mg pertuzumab/600 mg trastuzumab, via inj in the thigh over approx 8 minutes. Maintenance dose: 600 mg pertuzumab/600 mg trastuzumab every 3 weeks, given via inj in the thigh over approx 5 minutes for a total of 1 year (up to 18 cycles) or until disease recurrence or unmanageable toxicity occurs (whichever comes first). Missed dose: <6 weeks (time between 2 sequential inj): Administer maintenance dose as soon as possible then continue with the every 3 weeks schedule; ≥6 weeks (time between 2 sequential inj): Readminister loading dose followed by maintenance doses of every 3 weeks thereafter. Switching from IV pertuzumab and trastuzumab: <6 weeks since last IV pertuzumab and trastuzumab dose: Administer SC maintenance dose and every 3 weeks for subsequent administrations; ≥6 weeks since last IV pertuzumab and trastuzumab dose: Administer SC loading dose followed by SC maintenance doses of every 3 weeks for subsequent administrations. Dosing interruption, or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline).
Subcutaneous
HER2-positive locally recurrent unresectable carcinoma of breast, HER2-positive metastatic carcinoma of breast
Adult: Available preparations:
Pertuzumab 600 mg and trastuzumab 600 mg per 10 mL of solution for inj
Pertuzumab 1,200 mg and trastuzumab 600 mg per 15 mL of solution for inj
In combination with docetaxel, in patients who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease: Loading dose: 1,200 mg pertuzumab/600 mg trastuzumab, via inj in the thigh over approx 8 minutes. Maintenance dose: 600 mg pertuzumab/600 mg trastuzumab every 3 weeks, given via inj in the thigh over approx 5 minutes. Continue treatment until disease progression or unacceptable toxicity occurs. Missed dose: <6 weeks (time between 2 sequential inj): Administer maintenance dose as soon as possible then continue with the every 3 weeks schedule; ≥6 weeks (time between 2 sequential inj): Readminister loading dose followed by maintenance doses of every 3 weeks thereafter. Switching from IV pertuzumab and trastuzumab: <6 weeks since last IV pertuzumab and trastuzumab dose: Administer SC maintenance dose and every 3 weeks for subsequent administrations; ≥6 weeks since last IV pertuzumab and trastuzumab dose: Administer SC loading dose followed by SC maintenance doses of every 3 weeks for subsequent administrations. Dosing interruption, or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline).
Pertuzumab 600 mg and trastuzumab 600 mg per 10 mL of solution for inj
Pertuzumab 1,200 mg and trastuzumab 600 mg per 15 mL of solution for inj
In combination with docetaxel, in patients who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease: Loading dose: 1,200 mg pertuzumab/600 mg trastuzumab, via inj in the thigh over approx 8 minutes. Maintenance dose: 600 mg pertuzumab/600 mg trastuzumab every 3 weeks, given via inj in the thigh over approx 5 minutes. Continue treatment until disease progression or unacceptable toxicity occurs. Missed dose: <6 weeks (time between 2 sequential inj): Administer maintenance dose as soon as possible then continue with the every 3 weeks schedule; ≥6 weeks (time between 2 sequential inj): Readminister loading dose followed by maintenance doses of every 3 weeks thereafter. Switching from IV pertuzumab and trastuzumab: <6 weeks since last IV pertuzumab and trastuzumab dose: Administer SC maintenance dose and every 3 weeks for subsequent administrations; ≥6 weeks since last IV pertuzumab and trastuzumab dose: Administer SC loading dose followed by SC maintenance doses of every 3 weeks for subsequent administrations. Dosing interruption, or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline).
Subcutaneous
Neoadjuvant treatment of early stage HER2-positive carcinoma of breast, Neoadjuvant treatment of inflammatory HER2-positive carcinoma of breast, Neoadjuvant treatment of locally advanced HER2-positive carcinoma of breast
Adult: Available preparations:
Pertuzumab 600 mg and trastuzumab 600 mg per 10 mL of solution for inj
Pertuzumab 1,200 mg and trastuzumab 600 mg per 15 mL of solution for inj
In combination with chemotherapy, in patients at high risk of recurrence: Loading dose: 1,200 mg pertuzumab/600 mg trastuzumab, via inj in the thigh over approx 8 minutes. Maintenance dose: 600 mg pertuzumab/600 mg trastuzumab every 3 weeks, given via inj in the thigh over approx 5 minutes for 3-6 cycles, depending on the chosen regimen. Missed dose: <6 weeks (time between 2 sequential inj): Administer maintenance dose as soon as possible then continue with the every 3 weeks schedule; ≥6 weeks (time between 2 sequential inj): Readminister loading dose followed by maintenance doses of every 3 weeks thereafter. Switching from IV pertuzumab and trastuzumab: <6 weeks since last IV pertuzumab and trastuzumab dose: Administer SC maintenance dose and every 3 weeks for subsequent administrations; ≥6 weeks since last IV pertuzumab and trastuzumab dose: Administer SC loading dose followed by SC maintenance doses of every 3 weeks for subsequent administrations. Dosing interruption, or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline).
Pertuzumab 600 mg and trastuzumab 600 mg per 10 mL of solution for inj
Pertuzumab 1,200 mg and trastuzumab 600 mg per 15 mL of solution for inj
In combination with chemotherapy, in patients at high risk of recurrence: Loading dose: 1,200 mg pertuzumab/600 mg trastuzumab, via inj in the thigh over approx 8 minutes. Maintenance dose: 600 mg pertuzumab/600 mg trastuzumab every 3 weeks, given via inj in the thigh over approx 5 minutes for 3-6 cycles, depending on the chosen regimen. Missed dose: <6 weeks (time between 2 sequential inj): Administer maintenance dose as soon as possible then continue with the every 3 weeks schedule; ≥6 weeks (time between 2 sequential inj): Readminister loading dose followed by maintenance doses of every 3 weeks thereafter. Switching from IV pertuzumab and trastuzumab: <6 weeks since last IV pertuzumab and trastuzumab dose: Administer SC maintenance dose and every 3 weeks for subsequent administrations; ≥6 weeks since last IV pertuzumab and trastuzumab dose: Administer SC loading dose followed by SC maintenance doses of every 3 weeks for subsequent administrations. Dosing interruption, or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline).
